|
Sekunjalo Investments Limited - Sekunjalo Enters Marketing And Distribution Agreement With Unichem Sekunjalo Investments Limited (Incorporated in the Republic of South Africa) (Registration number 1996/006093/06) Share code: SKJ & ISIN: ZAE000017893 (`Sekunjalo` or `the company`) Media Release: SEKUNJALO ENTERS MARKETING & DISTRIBUTION AGREEMENT WITH UNICHEM Sekpharma, the Health Care subsidiary of Sekunjalo Investments Limited, announced today that it has entered a marketing and distribution agreement with one of the leading India`s pharmaceutical multinationals - Unichem Laboratories Limited for the Southern African market. Mr. Muzi Nkosi, CEO of Sekunjalo Healthcare said that this agreement with Unichem is significant keeping in view the increasing demand for quality and affordable generics in the global markets including South Africa. This arrangement is expected to contribute significantly to the revenue flows of Sekpharma over the next 5 years and will strengthen the portfolio of the ethical and generic range being offered by Sekpharma. Unichem has in its portfolio a range of generic products that span the various therapeutic categories being prescribed by the physician. Many of these products are under the registration process and are expected to be launched over the next couple of years in South Africa. The initial 5 products which this partnership is planning to launch in South Africa over the next 6 months represents a market potential of R110 million with excellent growth prospects. Unichem Laboratories Limited is an Indian pharmaceutical company with vertically integrated operations. The company develops, manufactures and markets finished dosage formulations and active pharmaceutical ingredients in anti-infective, cardiovascular, psychiatry and neurology in India and overseas. Unichem is also engaged in research and development of new drug delivery systems and development of non-infringing process for active pharmaceutical ingredients. In South Africa, it operates through its subsidiary company - Unichem SA (Pty) Ltd, which is the holding company for all the registrations. Unichem does not plan to put up any infrastructure in South Africa, instead would depend on this relationship to market the products in the region. It is the intention of the company to be in line with the current changes in the South African climate which places more emphasis on black empowerment and which is why it chose to partner with one of the leading black owned pharmaceutical marketing companies. Mr. Nkosi said that this relationship is strategic and would enable Sekpharma to tap into the Unichem portfolio and position itself as a serious player in the pharmaceutical sector. He also stated that this agreement follows the acquisition by Sekpharma of the pharmaceutical brands of Glaxo Smith Kline in 2000 which include the leading injectable antibiotic - Fortum, The dermatology range - Dermovate, Betnovate, Eumovate & The Asthma range - that include Becotide and Becloforte. Mr. Nkosi also announced that Sekunjalo Healthcare would aggressively increase its position over the next few months and has identified the area of infectious diseases to offer affordable solutions to the people of Southern Africa. Dr. Surve, the CEO of Sekunjalo Investments Limited congratulates Mr Nkosi for growing Sekpharma and for his acquisitive growth strategy. Dr. Surve has said that Mr. Nkosi is leading the Sekpharma team into a potential listing on the JSE and Sekpharma has been approached to consider listing with other listed pharmaceutical companies. Dr. Surve also stated that Mr. Nkosi, the CEO of Sekpharma and Sekunjalo Healthcare for the last 3 years has also been recently appointed to the main board of Sekunjalo Investments Limited, the holding company of the group. For further information Melody Mjila Group Communications Manager Sekunjalo Investments Limited. Tel: 021 658 2700 Date: 25/08/2005 12:10:28 PM Produced by the JSE SENS Department
| Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information. | |||||||||||||
| Other Profile Group sites: FundsData Online (unit trust data) | Profile Group corporate site | |||||||||||||
| [ Terms of Use | Privacy Policy | PAIA manual | FAQs/Help | Site Map | © Copyright Reserved 2026 ] | |||||||||||||
|
|||||||||||||
